The following is a list of milestone documents, compiled by the National HPV Vaccination Roundtable, which chronicles notable events in U.S.-based HPV vaccine history, from 2006 to present.
Launch of the global strategy to accelerate the elimination of cervical cancer
On November 17, 2020, following the close of the 73rd World Health Assembly, WHO officially launched the cervical cancer global elimination strategy. Due to the pandemic. the event was held virtually and hosted by WHO leadership. The governments of Australia, Botswana, Lesotho, Malawi, Nigeria, and Rwanda co-sponsored the event.
ACIP updates recommendation to harmonize HPV vaccination and to add shared clinical decision making for adults 27-45
President's Cancer Panel issues a report: HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action
Cancer Moonshot Blue Ribbon Panel Report highlights cancer prevention potential of HPV vaccination
FDA approves nine valent vaccination (9vHPV/Gardasil 9)
Gardasil 9 package insert: Link
National HPV Vaccination Roundtable established by the American Cancer Society and the Centers for Disease Control and Prevention
President’s Cancer Panel issues 2012-2013 Report: Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer
FDA licenses quadrivalent HPV vaccine (HPV4/Gardasil) for use in males aged 9 through 26 years for prevention of genital warts on October 16, 2009
Advisory Committee on Immunization Practices (ACIP) issues recommendations on quadrivalent HPV vaccine